Sonal Bhatia from Pfizer: Eliquis Continues to Show Positive Results in Real World Trials

It has been several years since Eliquis was approved as an oral anticoagulant but still more research is being done to show its benefits in helping patients with non-valvular atrial fibrillation.

Sonal Bhatia, MD, from Pfizer discussed the results of this additional research during the American College of Cardiology's annual meeting in Chicago. While Warfarin may still be the preferred treatment method for some patients Bhatia said the results of their studies showed that oral anticoagulants are a viable option for many patients as well.